GENEVA, March 26, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a ...

GENEVA, March 26, 2025--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...

Corneal disease is the primary cause of visual loss in allergic eye disease. It occurs almost exclusively in vernal keratoconjunctivitis and atopic keratoconjunctivitis. It is characterized by ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...

The indication for insertion of ProKera was nonhealing corneal ulcers of infective origin (group 1) in 9 eyes (25.7%), neurotrophic keratopathy (group 2) in 11 eyes (31.4%), chemical injury (group ...

Aurion's AURN001, an allogeneic cell therapy for corneal edema, is advancing to phase 3 trials in 2025, having received FDA Breakthrough Therapy Designation. Arnaud Lacoste, PhD, is appointed CEO of ...

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades. In celebration of ...